Mount Sinai Newsroom
Researchers at Mount Sinai School of Medicine have found that a compound called NIC5-15, might be a safe and effective treatment to stabilize cognitive performance in patients with mild to moderate Alzheimer's disease. The two investigators, Giulio Maria Pasinetti, M.D., Ph.D. , and Hillel...
FDA approval of the new Alzheimer's treatment, which will be branded as Kisunla, follows years of setbacks.
Swedish researchers showed promising results for a new, less invasive Alzheimer's blood test. July 28, 2024 Additional Live Streams Additional Live Streams Live ABC News Live Live View of Dolby Theatre in Los Angeles amid wildfire outbreak
Researchers at the University of Illinois have identified a potential drug target for the treatment of Alzheimer's disease: a receptor that is embedded in the membrane of neurons and other cells. A protein fragment associated withAlzheimer's diseaseactivates this receptor, sparking increased activity ...
Cisd2: a promising new target in Alzheimer's disease 来自 Wiley 喜欢 0 阅读量: 40 作者:A Nobili,P Krashia,M D'Amelio 摘要: The CISD2 gene encodes the CDGSH iron-sulfur domain-containing protein 2. Cisd2 is involved in mammalian lifespan control, the unfolded protein response, Ca2+ ...
题目 Could a new treatment developed by the US company Lilly mean "the beginning of the end" of Alzheimer's (阿尔兹海默症)?Could we even cure it some day?These are headlines and questions swirling (流传) around after news of a new drug,called donanemab,showed promising r...
LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. ...
Alzheimer's disease is the most common cause of dementia, affecting more than 55 million people worldwide. Currently, the two main approaches for treatments to delay or slow its progression target the buildup of amyloid beta peptides—which form plaques
This project did not involve any medications. The ultrasound itself was enough to elicit a probable immunological response. In the future, however, the treatment may make it easier to medicate the brain with more precision, even in people who don't have Alzheimer's disease. ...